Insights for precision oncology from the integration of genomic and clinical data of 13,880 tumors from the 100,000 Genomes Cancer Programme

Alona Sosinsky,John Ambrose,William Cross,Clare Turnbull,Shirley Henderson,Louise Jones,Angela Hamblin,Prabhu Arumugam,Georgia Chan,Daniel Chubb,Boris Noyvert,Jonathan Mitchell,Susan Walker,Katy Bowman,Dorota Pasko,Marianna Buongermino Pereira,Nadezda Volkova,Antonio Rueda-Martin,Daniel Perez-Gil,Javier Lopez,John Pullinger,Afshan Siddiq,Tala Zainy,Tasnim Choudhury,Olena Yavorska,Tom Fowler,David Bentley,Clare Kingsley,Sandra Hing,Zandra Deans,Augusto Rendon,Sue Hill,Mark Caulfield,Nirupa Murugaesu

DOI: https://doi.org/10.1038/s41591-023-02682-0

IF: 82.9

2024-01-12

Nature Medicine

Abstract:The Cancer Programme of the 100,000 Genomes Project was an initiative to provide whole-genome sequencing (WGS) for patients with cancer, evaluating opportunities for precision cancer care within the UK National Healthcare System (NHS). Genomics England, alongside NHS England, analyzed WGS data from 13,880 solid tumors spanning 33 cancer types, integrating genomic data with real-world treatment and outcome data, within a secure Research Environment. Incidence of somatic mutations in genes recommended for standard-of-care testing varied across cancer types. For instance, in glioblastoma multiforme, small variants were present in 94% of cases and copy number aberrations in at least one gene in 58% of cases, while sarcoma demonstrated the highest occurrence of actionable structural variants (13%). Homologous recombination deficiency was identified in 40% of high-grade serous ovarian cancer cases with 30% linked to pathogenic germline variants, highlighting the value of combined somatic and germline analysis. The linkage of WGS and longitudinal life course clinical data allowed the assessment of treatment outcomes for patients stratified according to pangenomic markers. Our findings demonstrate the utility of linking genomic and real-world clinical data to enable survival analysis to identify cancer genes that affect prognosis and advance our understanding of how cancer genomics impacts patient outcomes.

biochemistry & molecular biology,cell biology,medicine, research & experimental

What problem does this paper attempt to address?

This paper aims to solve key problems in precision oncology by integrating genomics and clinical data. Specifically, the research team analyzed whole - genome sequencing (WGS) data of 13,880 tumor samples from the UK 100,000 Genomes Project Cancer Programme, which covered 33 different types of cancer. The main objectives of the study include:

1. **Evaluating the application of genomics in precision cancer treatment**: By combining WGS data with real - world clinical treatment and outcome data, the research team hopes to identify gene mutations that can affect patient prognosis and further understand how genomics affects patient treatment outcomes.

2. **Identifying the frequency of gene mutations in different cancer types**: The study found that there are significant differences in the incidence of somatic mutations in genes recommended for standard testing among different cancer types. For example, in glioblastoma multiforme, small variants are present in 94% of cases, and copy - number abnormalities in at least one gene are present in 58% of cases; while in sarcoma, the incidence of actionable structural variants is the highest, reaching 13%.

3. **The importance of combining somatic and germ - line analysis**: The study emphasizes the value of performing somatic and germ - line analysis simultaneously. For example, in high - grade serous ovarian cancer, 40% of cases have homologous recombination defects, of which 30% are related to pathogenic germ - line variants.

4. **Linking genomics and real - world clinical data to evaluate treatment efficacy**: By combining WGS data with long - term life - course clinical data, the research team was able to evaluate the treatment efficacy of patients stratified according to pan - genomic markers. This is helpful for survival analysis, thereby identifying cancer genes that affect prognosis and advancing our understanding of how cancer genomics affects patient outcomes.

Overall, this study, through large - scale integration of genomics and clinical data, demonstrates the great potential of genomics in precision oncology and provides an important reference for future clinical practice.